These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 25439370)

  • 1. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
    Divekar R; Butterfield J
    Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
    Butterfield JH; Weiler CR
    Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
    Butterfield JH
    Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
    Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
    Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
    Giannetti MP; Akin C; Hufdhi R; Hamilton MJ; Weller E; van Anrooij B; Lyons JJ; Hornick JL; Pinkus G; Castells M; Pozdnyakova O
    J Allergy Clin Immunol; 2021 Apr; 147(4):1497-1501.e1. PubMed ID: 33248113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes.
    Picard M; Giavina-Bianchi P; Mezzano V; Castells M
    Clin Ther; 2013 May; 35(5):548-62. PubMed ID: 23642289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
    Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
    J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human mast cell tryptase in biology and medicine.
    Vitte J
    Mol Immunol; 2015 Jan; 63(1):18-24. PubMed ID: 24793463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tryptase: A practical guide for the physician].
    Lobbes H; Reynaud Q; Mainbourg S; Lega JC; Durieu I; Durupt S
    Rev Med Interne; 2020 Nov; 41(11):748-755. PubMed ID: 32712042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of plasma heparin level improves identification of systemic mast cell activation disease.
    Vysniauskaite M; Hertfelder HJ; Oldenburg J; Dreßen P; Brettner S; Homann J; Molderings GJ
    PLoS One; 2015; 10(4):e0124912. PubMed ID: 25909362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
    Butterfield JH; Ravi A; Pongdee T
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tryptase level is a better predictor of systemic side effects than prostaglandin D2 metabolites during venom immunotherapy in children.
    Cichocka-Jarosz E; Sanak M; Szczeklik A; Brzyski P; Gielicz A; Pietrzyk JJ
    J Investig Allergol Clin Immunol; 2011; 21(4):260-9. PubMed ID: 21721371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence of mast cell clonality in patients with unexplained anaphylaxis.
    Gülen T; Hägglund H; Sander B; Dahlén B; Nilsson G
    Clin Exp Allergy; 2014 Sep; 44(9):1179-87. PubMed ID: 25039926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell tryptase in sera of patients with Crohn's disease and mastocytosis.
    de Rossi TM; Krauss N; Wilken V; Giera B; Konturek PC; Kressel J; Hahn EG; Raithel M
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):273-7. PubMed ID: 19279472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia.
    Giannetti MP; Godwin G; Weller E; Butterfield JH; Castells M
    J Allergy Clin Immunol; 2022 Nov; 150(5):1225-1227. PubMed ID: 35550148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
    Valent P; Akin C; Arock M
    Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent PGD
    Butterfield JH; Singh RJ
    Prostaglandins Other Lipid Mediat; 2021 Aug; 155():106563. PubMed ID: 34029712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.